argenex SE (NASDAQ:ARGX) Receives $1,037.61 Average PT from Brokerages

argenex SE (NASDAQ:ARGX) has been given an average rating of “Moderate Buy” by the twenty-four brokerages that are currently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $1,050.50.

Several research analysts have commented on ARGX shares. Wall Street Zen upgraded shares of argenex from a “hold” rating to a “buy” rating in a report on Saturday. Guggenheim lifted their target price on shares of argenex from $1,135.00 to $1,185.00 and gave the company a “buy” rating in a research note on Friday. Citigroup boosted their price target on shares of argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Oppenheimer increased their price target on shares of argenex from $1,014.00 to $1,037.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, Wells Fargo & Company raised their price objective on shares of argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a report on Monday, June 1st.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC lifted its stake in shares of argenex by 3.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after purchasing an additional 83,568 shares during the period. M&T Bank Corp grew its stake in argenex by 20,977.7% in the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after purchasing an additional 774,916 shares during the period. Wellington Management Group LLP grew its stake in argenex by 80.1% in the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after purchasing an additional 324,653 shares during the period. Morgan Stanley raised its holdings in argenex by 19.2% in the fourth quarter. Morgan Stanley now owns 518,852 shares of the company’s stock worth $436,331,000 after purchasing an additional 83,746 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in argenex by 390.4% in the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after purchasing an additional 331,489 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

argenex Stock Down 0.7%

Shares of argenex stock opened at $918.22 on Tuesday. The company has a market cap of $57.44 billion, a PE ratio of 35.26, a P/E/G ratio of 1.13 and a beta of 0.45. The business has a 50 day moving average of $868.28 and a 200 day moving average of $815.12. argenex has a 52 week low of $587.37 and a 52 week high of $953.58.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, beating the consensus estimate of $5.86 by $1.46. The business had revenue of $1.54 billion for the quarter, compared to analysts’ expectations of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 70.27%. On average, research analysts anticipate that argenex will post 26.95 earnings per share for the current year.

argenex News Roundup

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex reported Q2 EPS of $7.32, topping estimates, on revenue of $1.54 billion versus expectations of $1.45 billion, highlighting strong operating momentum and profitability. Q2 earnings report and conference call
• Positive Sentiment: Reuters reported that global sales of Vyvgart jumped in the second quarter, a key driver for argenex’s growth and a major reason the stock has been gaining investor attention. Reuters article on Vyvgart sales
• Positive Sentiment: Oppenheimer, RBC, and Guggenheim all raised price targets and maintained bullish ratings, signaling increased Street confidence in argenex’s growth trajectory and pipeline prospects.
• Positive Sentiment: A Seeking Alpha note highlighted surging profitability, robust cash generation, and operational leverage, while pointing to pipeline catalysts such as empasiprubart as additional upside potential. Seeking Alpha rating upgrade article
• Neutral Sentiment: Short-interest data showed 0 shares reported, which provides little actionable signal for investors because the figures appear unchanged and unusually low.
• Negative Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932, though it still kept a positive rating, making this more of a minor caution than a bearish call.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.